Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine/Cedazuridine in BAP1 Cancer Predisposition Syndrome and Early-Stage Mesothelioma
NCT05960773Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2024
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inqovi in mesothelioma, BAP1 tumor predisposition syndrome (BAP1-TPDS), sponsored by National Cancer Institute. Started Jan 2024; status: recruiting.
02
Drugs
inqovi
03
Conditions
mesotheliomaBAP1 tumor predisposition syndrome (BAP1-TPDS)
Beyond the preview
Go deeper on NCT05960773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05960773.